（来源：廊坊日报） 本报讯（记者 杨巍 通讯员 李珍）近日，香河县中西医结合医院受邀参加2026年廊坊国际年货节，将中医药 文化与浓浓年味相结合，打造特色健康展区，为市民送上一份独特的"健康年礼"。 展区内，香河县中西医结合医院遵循古法技艺炮制的非遗膏方引人注目，自主研发的特色制剂、依据五行理 论制作的养生糕点等，吸引众多市民驻足了解、体验。 除了产品展示，医院还将专业服务带到现场。资深中医师坐镇，提供免费脉诊与健康咨询服务；中医体质辨 识仪凭借科学的个性化指导，成为备受青睐的"健康新宠"。 转自：廊坊日报 群众在展位前了解中药制品。本报通讯员 李珍 摄 ...

Core Insights - Lu Kang Pharmaceutical has focused on cultivating growth-oriented subsidiaries as a key strategic initiative to enhance innovation and core competitiveness over the past decade [1] - By 2024, the revenue of growth-oriented subsidiaries is expected to increase by 150% compared to 2018, becoming a significant driver of the company's development [1] Group 1: Strategic Focus - The company has identified "strategy + support + supervision" as three key areas to accelerate the development of subsidiaries, positioning various companies in specific leadership roles within their respective markets [2] - The company aims to strengthen supervision and support for growth-oriented subsidiaries, guiding them to establish modern corporate systems and new business models [2] Group 2: Transformation Initiatives - Lu Kang Pharmaceutical promotes six transformations for its growth-oriented subsidiaries, including transitioning from small to large enterprises and shifting focus from production to R&D and sales [3] - The largest subsidiary, She Li Le, has established a comprehensive system for research, production, and sales, ranking 14th globally among animal health companies in 2024 [3] Group 3: Support Models - The company implements a new support model characterized by precision, personalization, order-based assistance, and quantifiable indicators to enhance subsidiary development [4] - Five main lines of management are proposed to address bottlenecks in subsidiary development, ensuring comprehensive oversight in various operational aspects [4] Group 4: Performance Outcomes - Under the growth-oriented subsidiary strategy, significant achievements have been made, with sales revenue for Sai Te expected to double by 2024 compared to 2014 [5] - Qinghai Lu Kang Da Di is projected to see a 1.5 times increase in sales revenue by 2024 compared to 2014, while the biological pesticide segment anticipates a threefold revenue increase [5]